PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model
Open Access
- 23 June 2020
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy - Oncolytics
- Vol. 18, 226-235
- https://doi.org/10.1016/j.omto.2020.06.014
Abstract
No abstract availableKeywords
Funding Information
- Horizon 2020 programme of the European Commission (CARAT-667980)
- German Federal Ministry of Education and Research (IFB-01EO0803)
- Research Commission of the Faculty of Medicine of the Albert-Ludwigs-University of Freiburg (WOL1111/16)
This publication has 53 references indexed in Scilit:
- CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck ActivationMolecular Therapy, 2011
- CXCL12 Mediates Immunosuppression in the Lymphoma Microenvironment after Allogeneic Transplantation of Hematopoietic CellsCancer Research, 2010
- Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single‐chain diabodyThe Prostate, 2010
- Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune responseGene Therapy, 2010
- Preclinical Evaluation of a Recombinant Anti-Prostate Specific Membrane Antigen Single-Chain Immunotoxin Against Prostate CancerJournal of Immunotherapy, 2010
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor EradicationMolecular Therapy, 2010
- Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancerThe Prostate, 2009
- Target-dependent T-cell Activation by Coligation With a PSMA×CD3 Diabody Induces Lysis of Prostate Cancer CellsJournal of Immunotherapy, 2009
- Targeted Elimination of Prostate Cancer by Genetically Directed Human T LymphocytesCancer Research, 2005
- Anti‐prostate specific membrane antigen designer T cells for prostate cancer therapyThe Prostate, 2004